A chemically modified thrombolytic agent for reduced intracerebral bleeding risk

  • At: 2017 FIP Congress in Seoul (South Korea)
  • Type: Poster
  • By: KWON, Young (Nova Southeastern University, Pharmaceutical Sciences, College of Pharmacy, Fort Lauderdale, United States)
  • Co-author(s): Young M Kwon: Department of Pharmaceutical Sciences, College of Pharmacy, Nova Southeastern University, Fort Lauderdale, FL, United States
    Wael Mahdi: Department of Pharmaceutical Sciences, College of Pharmacy, Nova Southeastern University, Fort Lauderdale, FL, United States
    Gerardo Ramos: Department of Pharmaceutical Sciences, College of Pharmacy, Nova Southeastern University, Fort Lauderdale, FL, United States
  • Abstract:

    Background

    Tissue plasminogen activator (tPA) is the only FDA-approved drug for the treatment of ischemic stroke.  However, tPA is known to stimulate the production of matrix degrading enzymes, which may compromise the integrity of the blood-brain barrier (BBB), leading to intracerebral haemorrhage.  Therefore, a chemically modified thrombolytic..

  • The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress. Please login